Jazz Pharmaceuticals price target raised to $182 from $172 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $182 from $172 and keeps a Buy rating on the shares. Jazz reported in-line 3Q revenue and a sizeable non-GAAP net income beat despite results being negatively impacted by transient dynamics impacting the Rylaze brand, notes the firm, which thought Q3 results overall were “solid.” The firm thinks Jazz is set up attractively, trading at “highly depressed multiples,” yet offering mid-single digit sales and high-single digit bottom line compound annual growth rates.